Skip to Content

Vidaza (azacitidine) Disease Interactions

There are 4 disease interactions with Vidaza (azacitidine):

Major

Azacitidine (Includes Vidaza) ↔ Hepatic Tumors

Severe Potential Hazard, Moderate plausibility

Applies to: Hepatic Tumor

The use of azacitidine injection is contraindicated in patients with advanced malignant hepatic tumors.

Moderate

Azacitidine (Includes Vidaza) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Azacitidine is potentially hepatotoxic in patients with preexisting hepatic impairment and caution should be exercised when prescribing in patients with liver disease.

Moderate

Azacitidine (Includes Vidaza) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Patients with renal impairment may be at increased risk of renal toxicity when using azacitidine. This drug is primarily excreted by the kidneys. Therefore, these patients should be closely monitored for toxicity.

Moderate

Miscellaneous Antineoplastics (Includes Vidaza) ↔ Anemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Anemia, Neutropenia, Thrombocytopenia

Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia. Patients with these preexisting conditions should be monitored carefully. Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.

Vidaza (azacitidine) drug Interactions

There are 119 drug interactions with Vidaza (azacitidine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide